The biopharma industry experienced a lack of mergers & acquisitions (M&A) activity in 2024, with total values dropping by 51% despite a 17% increase in transactions. However, 2025 is expected to witness a surge in M&A dealmaking, due to factors such as patent expirations, changing political landscape, and companies’ need to diversify their portfolios and access new technologies. Experts believe large biopharma firms have reserved $1.3 trillion for such deals.
U.S. Secures Extradition of Rydox Cybercrime Marketplace Admins from Kosov
The US has extradited the administrators of the Rydox cybercrime marketplace from Kosovo. Brothers Ardit and Jetmir Kutleshi are to face charges in Pennsylvania over
